Amarin - חוב כולל להון AMRN

Amarin Corporation plc (AMRN) develops cardiology drugs, however, the expansion of generics undermines business scalability, forcing investments in legal protection. Fierce competition for market share creates significant risks for profits. This chart captures the debt-to-equity ratio at 0.01. The company is currently seeking cost optimization and new distribution channels in Europe due to stagnating sales in the US.

Amarin Corporation plc (AMRN) struggle against generics and cost optimization make debt load control critically important. This balance of debt and equity visualizes the business's degree of dependence on external creditors. The ratio is calculated as total liabilities relative to net shareholders' equity. An increase in this metric signals insolvency risks, while a decrease indicates financial recovery. Investors should evaluate this indicator as a marker of stability during operational stress.